← boardnext 2026-09
RAPP
Rapport Therapeutics Inc.distress 3/10 · well-funded / low risk$40.65-2%today-5% from 52w high
Neurology 1
Lead: focal onset seizures · target AMPA
Revenue
$20M
Liquidity
$477M
Runway
5.9 yrs
Shares 1y
+31%
Price & events
+45.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
+1.3%
1W
+4.6%
1M
+11.8%
3M
+50.9%
6M
+162.3%
1Y
+99.8%
2Y
—
5Y
+95.4%
All
Overview
- Market Cap
- $1.94B
- Volume
- 6.12K
- 52 Week Range
- $14.04 – $42.62
- Total Shares
- 47.83M
- Float Shares
- 31.79M
- Short %
- 7.49%
- % Held by Insiders
- 4.62%
- % Held by Institutions
- 109.50%
- RVOL
- 0.01x
- Beta
- 0.95
Pipeline stages · 1 programs
RAP-219
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | RAP-219 | Bipolar 1 Disorder | — | recruiting |
| 2028-02-03 Estimated 50% readout ~2028-03-19 | Phase 2 | RAP-219 | Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure | — | recruiting |
| 2029-07 Estimated 50% readout ~2029-09-14 | Phase 3 | RAP-219 | Focal Seizure, Epilepsy, Focal Epilepsy | — | recruiting |
| 2029-07 Estimated 50% readout ~2029-09-14 | Phase 3 | RAP-219 | Focal Seizure, Epilepsy, Focal Epilepsy | — | recruiting |
| 2025-09-26 | Phase 2 | RAP-219 | Focal Onset Seizures | 30 | completed |
Catalyst news & presentations · 16
- 2027Guided 40%readoutRAP-219 · Initial pharmacokinetic results for long-acting injectable formulationSEC 8-K
- first half of 2027Guided 55%trial initiationsecondaryPhase 3RAP-219 · Phase 3 trial initiation in PGTCSSEC 8-K
- first half of 2027Guided 55%readoutPhase 2RAP-219 · Topline results from Phase 2 trialSEC 8-K
- first half of 2027Guided 55%readoutPhase 2RAP-219 · Topline results from Phase 2 trialSEC 8-K
- second half of 2026Guided 55%readoutPhase 2RAP-219 · Preliminary results from open-label long-term safety trialSEC 8-K
- third quarter of 2026Guided 70%trial initiationsecondaryPhase 3RAP-219 · Initiate two Phase 3 pivotal trialsSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026trial initiationsecondaryPhase 3RAP-219 · Phase 3 program initiation for focal onset seizuresSEC 8-K
- April 21, 2026 at AAN Annual Meetingconferencedata presentationsecondaryPhase 2RAP-219 · Presentation of Phase 2a follow-up period results at AAN 2026SEC 8-K
- January 14, 2026conferencedata presentationsecondaryPresentation at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- fourth quarter of 2025filing acceptanceFiled (NDA/BLA)RAP-219 · End-of-Phase 2 meeting with FDASEC 8-K
- by the end of 2025trial initiationsecondaryPhase 2RAP-219 · Open-label long-term safety trial initiationSEC 8-K
- later in 2025enrollment completesecondaryRAP-219 · Update on plan and timeline for Phase 2 trial initiationSEC 8-K
- September 2025readoutPhase 2RAP-219 · topline results from Phase 2a trialSEC 8-K
- third quarter of 2025trial initiationsecondaryPhase 2RAP-219 · Initiate Phase 2a trial in Q3 2025SEC 8-K
- mid-2025readoutPhase 2RAP-219 · Topline data from Phase 2a proof-of-concept trial in refractory focal epilepsy.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $57 (+39% upside) · 11 analysts
- 2026-07-16BTIGBuy
- 2026-06-24Leerink PartnersOutperform
- 2026-05-21BTIGBuy
- 2026-05-08BTIGBuy
- 2026-04-22BTIGBuy
- 2026-03-11Wells FargoOverweight
Competitors — AMPA
- none identified
Recent news
- 2026-07-21Enterprise value to EBITDA forward of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
- 2026-07-18Analysts Offer Insights on NA Companies: Solv Energy (Nasdaq: MWH), Rapport Therapeutics, Inc. (RAPP) and Volvo Car AB Class B (OtherVLVOF) - The Globe and Mail
- 2026-07-18Rapport Therapeutics (RAPP) Q1 2026 earnings summary - Quartr
- 2026-07-16RAP-219’s Differentiated Mechanism Supports Unchanged $65 Price Target and Reiterated Buy on Rapport Therapeutics - TipRanks
- 2026-07-16RAPP Reiterates by BTIG -- Price Target Maintained at $65.00 - GuruFocus
- 2026-07-15Form 4 Rapport Therapeutics Inc For: 15 July By Investing.com - Investing.com Nigeria
- 2026-07-15Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock By Investing.com - Investing.com South Africa
- 2026-07-15Rapport Therapeutics CEO Ceesay Abraham sells $328,436 in stock - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.